Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4

Status

Terminated 2Withdrawn 1Unknown 1

Sponsor Class

NIH 6OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Glioblastoma 4Recurrence 2Glioma 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Cilengitide × Clear all
NCT01782976 2018-01-19

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNS

Glioblastoma, Recurrence

NCT01517776 2015-07-21

HGG-CilMetro

Martin-Luther-Universität Halle-Wittenberg

Phase 2 Terminated
28 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT01044225 2012-03-22

Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Universitair Ziekenhuis Brussel

Phase 2 Terminated
12 enrolled
CNS

Glioblastoma

NCT01124240 2011-07-26

ExCentric

Northern Sydney and Central Coast Area Health Service

Phase 2 Unknown
48 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡